FGF21 Is Not a Major Mediator for Bone Homeostasis or Metabolic Actions of PPARα and PPARγ Agonists

Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study

(2015) Jennifer Q. Dong et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Liver-Bone Endocrine Relay by IGFBP1 Promotes Osteoclastogenesis and Mediates FGF21-Induced Bone Resorption

(2015) Xunde Wang et al.   Cell Metabolism

Fibroblast Growth Factor 21 Prevents Atherosclerosis by Suppression of Hepatic Sterol Regulatory Element-Binding Protein-2 and Induction of Adiponectin in Mice

(2015) Z. Lin et al.   CIRCULATION

Skeletal muscle increases FGF21 expression in mitochondrial disorders to compensate for energy metabolic insufficiency by activating the mTOR–YY1–PGC1α pathway

(2015) Kunqian Ji et al.   FREE RADICAL BIOLOGY AND MEDICINE

Novel Insights into the Cardio-Protective Effects of FGF21 in Lean and Obese Rat Hearts

(2014) Vanlata Patel et al.   PLoS One

Differential Enzyme-Linked Immunosorbent Assay and Ligand-Binding Mass Spectrometry for Analysis of Biotransformation of Protein Therapeutics: Application to Various FGF21 Modalities

(2013) Todd Hager et al.   ANALYTICAL CHEMISTRY

Interactions between FGF21 and BMP-2 in osteogenesis

(2013) Kazunari Ishida et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The Effects of LY2405319, an FGF21 Analog, in Obese Human Subjects with Type 2 Diabetes

(2013) Gregory Gaich et al.   Cell Metabolism

Fibroblast growth factor 21 (FGF21) and bone: is there a relationship in humans?

(2013) P. Lee et al.   OSTEOPOROSIS INTERNATIONAL

Fibroblast growth factor 21 is not required for the antidiabetic actions of the thiazoladinediones

(2013) Andrew C. Adams et al.   Molecular Metabolism

Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones

(2012) Paul A. Dutchak et al.   CELL

Long-Acting FGF21 Has Enhanced Efficacy in Diet-Induced Obese Mice and in Obese Rhesus Monkeys

(2012) Murielle M. Véniant et al.   ENDOCRINOLOGY

Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor  

(2012) W. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The starvation hormone, fibroblast growth factor-21, extends lifespan in mice

(2012) Yuan Zhang et al.   eLife

Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin Resistance

(2011) Clarence Hale et al.   ENDOCRINOLOGY

Control of Steroid 21-oic Acid Synthesis by Peroxisome Proliferator-activated Receptor α and Role of the Hypothalamic-Pituitary-Adrenal Axis

(2009) Ting Wang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Circulating Fibroblast Growth Factor 21 Is Induced by Peroxisome Proliferator-Activated Receptor Agonists But Not Ketosis in Man

(2009) Constantinos Christodoulides et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Circulating Metabolic Regulator FGF21 Is Induced by Prolonged Fasting and PPARα Activation in Man

(2008) Cecilia Gälman et al.   Cell Metabolism

Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice

(2008) J. Xu et al.   DIABETES

Fibroblast Growth Factor 21 Corrects Obesity in Mice

(2008) Tamer Coskun et al.   ENDOCRINOLOGY

FGF21 N- and C-termini play different roles in receptor interaction and activation

(2008) Junming Yie et al.   FEBS LETTERS